hyperthermia, but the difference was not significant by paired t-test (p = 0.095). At least, increase of AST value after the infusion with hyperthermia was not observed (Fig . 3d) .
Discussion
Hyperthermia was attempted to treat primary or secondary liver tumors in some institute and some anti-tumor effect was reported 14) 15) Pirarubicin, in combination with 5Fu and folinic acid, is reported to be effective to treat some liver tumor 16). The combination therapy of hyperthermia and intra-hepatic infusion of pirarubicin might be effective in the treatment of liver tumors .
Pirarubicin, 4'-O-tetrahydropyranyl-adriamycin (THP-ADR), is developed to reduce cardiotoxicity of adriamycin 17) 18) and has equal anti-tumor activity with adriamycin 19). Pirarubicin is metabolized mainly in the liver and excreted mostly in bile 20) 21). When pirarubicin is administered from hepatic artery to treat hepatic tumor, the agent is extracted from liver and related with reduced systemic toxicity 22) Values of AST before the infusion minus after the infusion were compared between the infusion without and with hyperthermia in each patient.
AST values tend to decrease after the infusion with hyperthermia, but the difference was not significant by paired t-test (p = 0.095). At least, increase of AST after the infusion with hyperthermia was not observed. ( 6 ) 236
